Know Cancer

forgot password

Phase 2 Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Phase 2
18 Years
Not Enrolling
Kidney Neoplasms, Carcinoma, Renal Cell

Thank you

Trial Information

Phase 2 Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

Inclusion Criteria:

- RCC with metastases and nephrectomy

- failure of prior sorafenib-based therapy

- at least 1 target lesion that has not been irradiated

- adequate bone marrow, hepatic and renal function, > or equal to 18 years of age.

Exclusion Criteria:

- Gastrointestinal abnormalities

- current use or inability to avoid chronic antacid therapy

- current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2

- active seizure disorder or evidence of brain metastases.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Percentage of Participants With Objective Response (OR)

Outcome Description:

Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of responses. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum of longest dimensions.

Outcome Time Frame:

Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 152 weeks

Safety Issue:


Principal Investigator

Pfizer Call Center

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

March 2006

Completion Date:

June 2009

Related Keywords:

  • Kidney Neoplasms
  • Carcinoma, Renal Cell
  • Neoplasms
  • Carcinoma
  • Carcinoma, Renal Cell
  • Kidney Neoplasms



Pfizer Investigational Site Cincinnait, Ohio  45236
Pfizer Investigational Site Springfield, Illinois  62701-1014
Pfizer Investigational Site Bronx, New York  10461
Pfizer Investigational Site Kingston, Pennsylvania  18704-5535
Pfizer Investigational Site Milwaukee, Wisconsin  53215